Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment

Simona Nanni, Celestino Pio Lombardi, Alfredo Pontecorvi, Guido Fadda, Peter M. Sadow, Carmen Priolo, Florian A. Karreth, Mark Duquette, Roberta Martinelli, Amjad Husain, John Clohessy, Heinz Kutzner, Thomas Mentzel, Christopher V. Carman, Antonella Farsetti, Elizabeth Petri Henske, Emanuele Palescandolo, Laura E. Macconaill, Seum Chung, Antonina M. De AngelisOreste Durante, John A. Parker, Harold F. Dvorak, Christopher Fletcher, Pier Paolo Pandolfi, Jack Lawler, Carmelo Nucera

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Abstract

Myopericytoma (MPC) is a rare tumor with perivascular proliferation of pluripotent stem-cell-like pericytes. Although indolent, MPC may be locally aggressive with recurrent disease. The pathogenesis and diagnostic biomarkers of MPC are poorly understood. We discovered that 15% of benign MPCs (thyroid, skin; 3 of 20 samples) harbored BRAF(WT/V600E); 33.3% (1 of 3 samples) of BRAF(WT/V600E)-MPCs were multifocal/infiltrative/recurrent. Patient-MPC and primary MPC cells harbored BRAF(WT/V600E), were clonal and expressed pericytic-differentiation biomarkers crucial for its microenvironment. BRAF(WT/V600E)-positive thyroid MPC primary cells triggered in vitro (8.8-fold increase) and in vivo (3.6-fold increase) angiogenesis. Anti-BRAF(V600E) therapy with vemurafenib disrupted angiogenic and metabolic properties (~3-fold decrease) with down-regulation (~2.2-fold decrease) of some extracellular-matrix (ECM) factors and ECM-associated long non-coding RNA (LincRNA) expression, with no effects in BRAF(WT)-pericytes. Vemurafenib also inhibited (~3-fold decrease) cell viability in vitro and in BRAF(WT/V600E)-positive thyroid MPC patient-derived xenograft (PDX) mice (n = 5 mice per group). We established the first BRAF(WT/V600E)-dependent thyroid MPC cell culture. Our findings identify BRAF(WT/V600E) as a novel genetic aberration in MPC pathogenesis and MPC-associated biomarkers and imply that anti-BRAF(V600E) agents may be useful adjuvant therapy in BRAF(WT/V600E)-MPC patients. Patients with BRAF(WT/V600E)-MPC should be closely followed because of the risk for multifocality/recurrence.
Original languageEnglish
Pages (from-to)N/A-N/A
JournalJournal of the National Cancer Institute
Volume106
DOIs
Publication statusPublished - 2014

Keywords

  • Angiogenesis Inhibitors
  • Cell Line, Tumor
  • Cell Proliferation
  • Genotype
  • Glutamic Acid
  • Hemangiopericytoma
  • Humans
  • Indoles
  • Mass Spectrometry
  • Mutation
  • Neoplasm Recurrence, Local
  • Pericytes
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides
  • Thyroid Neoplasms
  • Tumor Markers, Biological
  • Valine
  • Xenograft Model Antitumor Assays

Fingerprint

Dive into the research topics of 'Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment'. Together they form a unique fingerprint.

Cite this